Bemnifosbuvir-Ruzasvir

Phase 3

00%

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

10mo

AVIRPhase 3$366M

Bemnifosbuvir-Ruzasvir Phase 3 Results Expected

Bemnifosbuvir-Ruzasvir• HEPATITIS C VIRUS CHRONIC INFECTION880

Dec 15Estimated

00%

Competitive Landscape

2 competitors in HEPATITIS C VIRUS CHRONIC INFECTION

Drug Information

Target Indication

HEPATITIS C VIRUS CHRONIC INFECTION

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

AVIR

Atea Pharmaceuticals, Inc.

Related Pipeline

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)

HEPATITIS C VIRUS CHRONIC INFECTION

Chronic Hepatitis C Virus

Hepatitis C